Your session is about to expire
← Back to Search
BAFFR-targeting CAR T Cells for B-Cell Lymphoma
Study Summary
This trial is testing a new treatment for mantle cell lymphoma, which uses CAR T cells to target BAFFR.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have an ongoing infection that needs treatment with antibiotics or antifungals.I am 18 years old or older.I am not pregnant or breastfeeding.I have a history of serious heart rhythm problems.I have had cancer before, but it's one of the exceptions.I have not had a stroke or brain bleed in the last 6 months.I can take care of myself and am up and about more than half of the day.I do not have any uncontrolled serious illnesses.I agree to use birth control methods if I can father a child.My cancer can be seen on a CT scan or is affecting my blood, GI tract, skin, bones, or spleen.I have recovered from side effects of previous cancer treatments.I had a stem cell transplant using my own cells within the last 6 months.I am currently using steroids or immunosuppressant medications regularly.I have had a blood clot in the past 6 months.I have severe heart problems that limit my daily activities.I have been diagnosed with a specific type of B-cell Non-Hodgkin's Lymphoma.I have had a stem cell transplant from a donor.I have an auto-immune disease and take medication to suppress my immune system.I have had optic neuritis or another immune-related brain condition.My lymphoma affects my heart.My kidneys are working well, as shown by a test.I need urgent treatment because my tumor is causing symptoms.I have had CNS involvement with my cancer within the last 3 months.My lymphoma cells show positive BAFF-R expression.I have previously undergone CAR T cell therapy.I have no allergies or adverse reactions to leukapheresis, steroids, or tocilizumab.
- Group 1: B-cell activating factor receptor-Chimeric antigen receptor T cells [BAFFR-CAR T cells]
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are researchers currently enrolling volunteers for this experiment?
"Yes, the clinicaltrials.gov entry for this trial reveals that it is actively recruiting participants. The public listing went up on June 13th 2022 and was recently adjusted on October 18th 2022; they are seeking 18 patients from a single research site."
Has the FDA sanctioned BAFFR-CAR T cells for clinical usage?
"The safety of BAFFR-CAR T cells is assumed to be a 1 since this clinical trial only recently began and data on efficacy and safety are limited."
What is the participant capacity of this medical experiment?
"Affirmative. Based on the information provided by clinicaltrials.gov, this medical research is currently seeking participants. The trial was initially posted on June 13th 2022 and most recently updated October 18th 2022 for a total of 18 enrollees from one site."
What results is the research team hoping to accomplish with this trial?
"The principal aim of this medical research, evaluated over a period spanning up to one year post-treatment, is the incidence of adverse events. The secondary outcomes encompass disease response as per Lugano Criteria, B cell quantification via flow cytometry and progression-free survival (PFS) estimated through Kaplan-Meier product limit method with log-log transformation for confidence interval analysis."
Share this study with friends
Copy Link
Messenger